We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Sekisui Diagnostics UK Ltd.

Download Mobile App




Adrenaline Use Discouraged as Heart Attack Treatment

By HospiMedica International staff writers
Posted on 31 Jul 2018
Print article
A new study shows that using adrenaline in cardiac arrests nearly doubles the survivors’ risk of severe brain damage.

Researchers at the University of Warwick (Coventry, United Kingdom), Royal United Hospital Bath (RUH; United Kingdom), the London Ambulance Service (United Kingdom), and other institutions conducted a study in five National Health Service (NHS) ambulance trusts in the United Kingdom. The study included 8,007 patients in cardiac arrest who were allocated randomly to be given either adrenaline or a salt-water placebo. All those involved in the trial, including ambulance crews and paramedics, were unaware which of the two treatments the patient received.

The results revealed that of 4,012 patients given adrenaline, 3.2% were alive at 30 days, compared with 2.4% of the 3,995 patients who were given placebo. Of the patients given adrenaline who survived to hospital discharge, 30.1% suffered severe brain damage, compared with 18.7% of survivors who had been given a placebo. Severe brain damage was defined as someone in a vegetative state requiring constant nursing care and attention, or unable to walk and look after their own bodily needs without assistance. The study was published on July 19, 2018, in the New England Journal of Medicine (NEJM).

“We found that the benefits of adrenaline are small, one extra survivor for every 125 patients treated, but the use of adrenaline almost doubles the risk of a severe brain damage amongst survivors,” said lead author Professor Gavin Perkins, MD, of the University of Warwick. “Patients may be less willing to accept burdensome treatments if the chances of recovery are small or the risk of survival with severe brain damage is high. Our own work with patients and the public before starting the trial identified survival without brain damage is more important to patients than survival alone.”

“This trial has answered one of the longest standing questions in resuscitation medicine. Taking the results in context of other studies, it highlights the critical importance of the community response to cardiac arrest,” said study co-author Professor Jerry Nolan, MD, consultant in anesthesia and intensive care medicine at RUH Bath. “Unlike adrenaline, members of the public can make a much bigger difference to survival through learning how to recognize cardiac arrest, perform CPR, and deliver an electric shock with a defibrillator.”

Once cardiac arrest is recognized, cardiopulmonary resuscitation (CPR) and defibrillation are applied without delay. The application of adrenaline is one of the last things attempted to treat cardiac arrest, in an effort to increase blood flow to the heart. At the same time, however, it also reduces blood flow in the brain, which may worsen brain damage. Observational studies involving over 500,000 patients have reported worse long-term survival and more brain damage among survivors who were treated with adrenaline.

Related Links:
University of Warwick
Royal United Hospital Bath
London Ambulance Service

Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Silver Member
Wireless Mobile ECG Recorder
NR-1207-3/NR-1207-E
New
Electric Bariatric Patient Lifter
SVBL 205

Print article

Channels

Surgical Techniques

view channel
Image: NeuroBlate NB3 FullFire 1.6mm laser probe is meant for use with the NeuroBlate System (Photo courtesy of Monteris Medical)

World’s Smallest Laser Probe for Brain Procedures Facilitates Ablation of Full Range of Targets

A new probe enhances the ablation capabilities for a broad spectrum of oncology and epilepsy targets, including pediatric applications, by incorporating advanced laser and cooling technologies to support... Read more

Patient Care

view channel
Image: The portable, handheld BeamClean technology inactivates pathogens on commonly touched surfaces in seconds (Photo courtesy of Freestyle Partners)

First-Of-Its-Kind Portable Germicidal Light Technology Disinfects High-Touch Clinical Surfaces in Seconds

Reducing healthcare-acquired infections (HAIs) remains a pressing issue within global healthcare systems. In the United States alone, 1.7 million patients contract HAIs annually, leading to approximately... Read more

Health IT

view channel
Image: First ever institution-specific model provides significant performance advantage over current population-derived models (Photo courtesy of Mount Sinai)

Machine Learning Model Improves Mortality Risk Prediction for Cardiac Surgery Patients

Machine learning algorithms have been deployed to create predictive models in various medical fields, with some demonstrating improved outcomes compared to their standard-of-care counterparts.... Read more

Point of Care

view channel
Image: The Quantra Hemostasis System has received US FDA special 510(k) clearance for use with its Quantra QStat Cartridge (Photo courtesy of HemoSonics)

Critical Bleeding Management System to Help Hospitals Further Standardize Viscoelastic Testing

Surgical procedures are often accompanied by significant blood loss and the subsequent high likelihood of the need for allogeneic blood transfusions. These transfusions, while critical, are linked to various... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.